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Abstract
Constitutional mismatch repair deficiency (CMMRD) is caused by germline pathogenic
variants in both alleles of a mismatch repair gene. Patients have an exceptionally high risk
of numerous pediatric malignancies and benefit from surveillance and adjusted treatment.
The diversity of its manifestation, and ambiguous genotyping results, particularly from
PMS2, can complicate diagnosis and preclude timely patient management. Assessment of
low‐level microsatellite instability in nonneoplastic tissues can detect CMMRD, but
current techniques are laborious or of limited sensitivity. Here, we present a simple,
scalable CMMRD diagnostic assay. It uses sequencing and molecular barcodes to detect
low‐frequency microsatellite variants in peripheral blood leukocytes and classifies samples
using variant frequencies. We tested 30 samples from 26 genetically‐confirmed CMMRD
patients, and samples from 94 controls and 40 Lynch syndrome patients. All samples were
correctly classified, except one from a CMMRD patient recovering from aplasia. However,
additional samples from this same patient tested positive for CMMRD. The assay also
confirmed CMMRD in six suspected patients. The assay is suitable for both rapid
CMMRD diagnosis within clinical decision windows and scalable screening of at‐risk
populations. Its deployment will improve patient care, and better define the prevalence
and phenotype of this likely underreported cancer syndrome.
K E YWORD S
Constitutional mismatch repair deficiency, genetic diagnostics, microsatellite instability,
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1 | INTRODUCTION
Constitutional mismatch repair deficiency (CMMRD) is a highly
penetrant cancer‐predisposition syndrome, caused by biallelic
germline pathogenic variants affecting one of the four mismatch
repair (MMR) genes: MLH1, MSH2, MSH6, or PMS2. CMMRD
typically manifests in childhood or adolescence as one of a broad
range of malignancies, primarily of the hematopoietic system and
brain, as well as colorectal and other cancers associated with
heterozygous germline MMR pathogenic variants (Lynch syn-
drome). Patients who survive their first malignancy have a high
risk of metachronous disease (Wimmer et al., 2014). Current
management guidelines recommend extensive surveillance from
early childhood, with 1–2 yearly clinical examinations that
include blood counts, optional abdominal ultrasound, brain MRI,
and gastrointestinal endoscopy. These guidelines also advocate
tailored treatment, such as extensive surgery to reduce the risk
of metachronous disease (Durno et al., 2017; Tabori et al., 2017;
Vasen et al., 2014), and there is evidence that immune checkpoint
blockade therapy is effective in these patients (Bouffet et al.,
2016). Aspirin intake may reduce cancer incidence in CMMRD,
although bleeding risks must be considered (Leenders et al.,
2018). Timely diagnosis of CMMRD is therefore important for
appropriate patient management.
CMMRD also has a broad spectrum of benign and nonneo-
plastic features that can be shared with other tumor‐predisposi-
tion syndromes. Most prevalent among these are abnormal skin
pigmentation reminiscent of neurofibromatosis type 1 (NF1) and
Legius syndrome (Wimmer, Rosenbaum, & Messiaen, 2017). These
features in childhood or adolescent cancer patients, as well as the
type of malignancy, consanguineous parents, and a family
history of Lynch syndrome cancers, are used for clinical diagnosis
according to criteria developed by the Care for CMMRD
(C4CMMRD) consortium (Wimmer et al., 2014). However,
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the phenotypic spectrum is broad and it is likely that the
clinical manifestation of CMMRD is not fully characterized (Durno
et al., 2017). Furthermore, the phenotypic overlap with NF1 and
Legius syndrome has led to the acknowledgment of CMMRD as a
legitimate, but presumably rare, differential diagnosis in children
without malignancy who are suspected of these syndromes but
lack the causative NF1 or SPRED1 variants (Suerink et al., 2019).
Family history can also be misleading as pathogenic variants in
PMS2, the gene implicated in more than 50% of CMMRD cases
(Wimmer et al., 2014), have a much lower penetrance than other
MMR variants in Lynch syndrome (Møller et al., 2017; Ten Broeke
et al., 2018). Hence, the C4CMMRD criteria were designed to have
high diagnostic sensitivity at the cost of specificity, and detection
of pathogenic variants in both alleles of an MMR gene is required
to confirm the diagnosis. Unfortunately, molecular genetic testing
is not always definitive, and the diagnosis of CMMRD is frequently
confounded by MMR variants of unknown significance (VUS) and
pseudogenes of PMS2 (De Vos, Hayward, Picton, Sheridan, &
Bonthron, 2004), which is a recognized “dead zone” for diagnostic
next‐generation sequencing (Mandelker et al., 2016).
The need to resolve diagnostic ambiguities has led to the
development of highly sensitive microsatellite instability (MSI)
assays, such as germline MSI (gMSI; Ingham et al., 2013) and ex
vivo MSI (evMSI; Bodo et al., 2015), that detect low‐frequency
microsatellite length variants in nonneoplastic tissues, a hallmark of
CMMRD. gMSI is a simple PCR‐based assay using template DNA
from peripheral blood leukocytes (PBLs), but analyses dinucleotide
repeats that are insensitive to loss of MSH6 activity (Ingham et al.,
2013). evMSI uses mononucleotide repeats that are sensitive for
deficiency of any MMR protein, but requires a long‐term culture of
primary lymphoblastoid cell lines and parallel analysis of alkylation
tolerance (Bodo et al., 2015). There is a need for an MSI assay that is
both accurate and simple, to assess the functionality of the MMR
system within clinical decision windows. Furthermore, perhaps as a
result of diagnostic difficulties, CMMRD is likely to be under-
diagnosed. Recent epidemiological studies estimate that carriers of
MMR pathogenic variants are relatively common (up to 1 in 279 of
the general population), and that carriers of PMS2 variants are
the most common among these (Win et al., 2017). In addition,
germline pathogenic variants in DNA repair genes, including those of
the MMR system, are the most prevalent germline genetic cause of a
variety of pediatric cancers (Gröbner et al., 2018). Despite this, only
approximately 200 cases of CMMRD are known. Therefore, func-
tional assays for CMMRD should, ideally, be applicable to patient
screening at scale, to address its underdiagnosis.
We have previously described a novel panel of short
microsatellites for accurate detection of MSI in colorectal
cancers (CRCs), using high‐throughput sequencing and auto-
mated analysis (Redford et al., 2018). Here, we show that a subset
of these markers, analyzed using molecular barcoding of sequen-
cing reads to facilitate reduction of PCR and sequencing error,
can detect low‐frequency microsatellite length variants in PBLs
for the diagnosis of CMMRD.
2 | PATIENTS AND METHODS
Thirty DNA samples extracted from PBLs were available from 26
genetically or functionally‐confirmed CMMRD patients (with three
patients having multiple samples analyzed), and six samples were
obtained from six suspected CMMRD patients with MMR missense
VUS that lacked functional data to support pathogenicity (Table S1).
This cohort constitutes approximately 15% of known cases (Wimmer
et al., 2017) and includes biallelic pathogenic variants in each of the
four MMR genes. Non‐CMMRD control PBL DNAs consented for use
in assay development, were provided by 94 anonymized patients
consulted for noncancer‐related conditions at the Medical University
of Innsbruck. All CMMRD and control samples were collected and
analyzed following ethical review by the Medical University of
Innsbruck review board. Forty DNAs extracted from the PBLs of
adult Lynch syndrome patients were received from the CaPP3
clinical trial (ISRCTN16261285) biobank and analyzed following an
ethical review by the Newcastle University research ethics commit-
tee (REC reference 13/LO/1514). Full cohort details, including
patient genotype, pertinent clinical history, and assay results, can
be found in Table S2.
A panel of 24 short (7–12 bp), monomorphic, mononucleotide
repeats (Table S3) were selected from the markers described by
Redford et al. (2018). These were amplified from 100 ng of each
sample using a multiplex of single molecule molecular inversion
probes (smMIPs), following the protocol of Hiatt, Pritchard, Salipante,
O'Roak, and Shendure (2013) with minor modifications: Herculase II
Polymerase (Agilent, Santa Clara, CA) was used during extension and
amplification steps, and amplification thermocycling used 98°C for
2min, 30 cycles of 98°C for 15 s, 60°C for 30 s, and 72°C for 30 s,
followed by 72°C for 2 min. Amplicons were purified using Agencourt
AMPure XP Beads (Beckman Coulter, Brea, CA), pooled, and
sequenced to a mean depth (±SD) of 3,642 ± 1,659 reads/marker/
sample on a MiSeq (Illumina, San Diego, CA). Fastq files are available
from the European Nucleotide Archive, accession number:
PRJEB28798. Reads were aligned to reference genome hg19 using
BWA v0.6.2 (Li & Durbin, 2010). smMIPs add molecular barcodes to
amplicons to reduce sequencing error (Hiatt et al., 2013), and these
were used to facilitate the detection of low‐frequency microsatellite
length variants (Supporting Information S1).
The scarcity of CMMRD samples precluded classifier training and
validation in independent cohorts, as described by Redford et al.
(2018). As an alternative, we modeled the distribution of the relative
frequency of reads containing the WT length of microsatellite (WT
reads) for each marker in the first 40 control samples analyzed (see
Results). To classify samples, we used these distributions to estimate
the probability of an observed frequency of WT reads in a sample
being greater than or equal to that of the control set. For each
sample, the probabilities from the 24 markers were combined using
Fisher's method to estimate the overall probability that a sample is
from the control population. For ease of interpretation and
presentation, we multiplied the decadic logarithm of this probability
by minus one, and designated the transformed value as the score.
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Higher scores indicate increased MSI and, therefore, an increased
likelihood of CMMRD. Details of the method are given in Supporting
Information S2. The analysis was performed in R v3.3.1. The Beta
distribution was used to model the control distribution of WT read
frequencies, with distribution parameters calculated by the eBeta
function of the ExtDist package. The metap package sumlog function
was used to combine probabilities derived from these distributions
by Fisher's method. R scripts are available upon request.
Transcript analysis was used to support variant pathogenicity for
a subset of MMR missense VUS, following protocols described by
Etzler et al. (2008).
3 | RESULTS
An initial cohort of 40 controls, together with five CMMRD samples,
were analyzed as proof of principle of the method (Supporting
Information S2). Subsequently, a second cohort of the remaining 27
CMMRD patients and 54 controls were analyzed blind to sample
status. Results from both cohorts are presented together in Figure 1.
All samples from the 26 genetically or functionally‐confirmed
CMMRD patients (score = 1.59–54.55) were separable from controls
(score = 0.00–1.47; Figure 1). For CMMRD diagnosis, an a priori
threshold of 5% probability that the sample is from the control
population (score threshold = 1.30) achieved 100% sensitivity and
98% specificity across all samples (Figure 1). The more conservative
threshold of 1% probability (score threshold = 2.00) failed to
detect only one CMMRD sample (97% sensitivity, 100% specificity,
Figure 1). However, this sample is one of three collected from Patient
8 when they were recovering from aplasia due to chemotherapy for
T cell lymphoma (Figure 1, marked §). The other two samples also had
low scores, but correctly identified patient 8 as CMMRD by the score
threshold of 2.00. Patients 29, 30, and 31 are homozygous for a
hypomorphic PMS2 variant, shown to cause an attenuated CMMRD
phenotype in the Nunavik Inuit population (Li et al., 2015). Their
samples were correctly classified but had relatively low scores (2.76–
5.90; Figure 1, marked †).
The six patients with MMR missense VUS suspected of CMMRD
had scores ranging from 10.02 to 53.72 (Figure 1), consistent with
their clinical diagnosis. For the two MSH6 VUS, p.Asp439Gly and p.
Tyr994Asn, and the PMS2 VUS p.Gln700Arg, transcript analysis
(Etzler et al., 2008) was used to exclude the presence of a different
causative variant, such as deep intronic variants that lead to altered
messenger RNA splicing, or regulatory variants that lead to the loss
of expression of one allele that would be undetected by analysis of
genomic DNA. The reclassification of these MMR missense VUS as
(likely) pathogenic, at least in the context of CMMRD, should be
considered (Table S1). Exclusion of a different causative variant by
transcript analysis also supported the pathogenicity of the MLH1
variant p.Val716Met in Patient 5, who has previously been confirmed
as CMMRD (unpublished data) by the gMSI assay (Ingham et al.,
2013). This variant, which has previously been identified as
potentially disease‐causing in the context of CMMRD (Marcos,
Borrego, Urioste, García‐Vallés, & Antiñolo, 2006), is classified as
benign (Class 1) by the InSiGHT variant interpretation committee in
the context of Lynch syndrome (Table S1).
As an independent confirmation of our results, we analyzed all
CMMRD and control samples with the gMSI assay (Ingham et al.,
2013). gMSI results were concordant with our findings, except for
the 15 samples from patients with loss of MSH6 (Table S2), for which
gMSI is known to be insensitive. Increased MSI has also been
detected in the PBLs of Lynch syndrome patients relative to the
general population using small pool PCR (Coolbaugh‐Murphy et al.,
2010). To assess whether or not the assay would be able to
discriminate between Lynch syndrome and CMMRD, we tested DNA
extracted from the PBLs of 40 adult patients with confirmed
pathogenic variants in one allele of an MMR gene. These patients
scored 0.00–0.92, and were, therefore, distinct from the CMMRD
patients analyzed and indistinguishable from controls (Figure 1).
4 | DISCUSSION
We have previously shown that short (7–12 bp) mononucleotide
repeats facilitate highly accurate MSI testing of CRC (Redford et al.,
2018), and here show that they can detect low‐frequency micro-
satellite length variants in PBLs to diagnose CMMRD, using a smMIP‐
based assay. The assay produces an easy‐to‐read score, equivalent to
the probability that a sample is distinct from the non‐CMMRD,
control population. Using an a priori score threshold of 2.00, only one
CMMRD sample was missed, which was collected from a patient
recovering from aplasia. Repeat samples from this patient were
correctly classified as CMMRD but also had low scores, suggesting a
reduced frequency of microsatellite length variants in their PBLs.
This is consistent with the observation that MMR deficient
hematopoietic stem cells with a higher burden of microsatellite
mutations are associated with defective repopulation (Reese, Liu, &
Gerson, 2003). An alternative explanation is that repopulating
leukocytes have acquired fewer microsatellite length variants due
to fewer cycles of DNA replication, following the polymerase slippage
model of microsatellite mutation (Fan & Chu, 2007). It may,
therefore, be appropriate to treat low scores in patients suspected
of CMMRD who are aplastic, or recovering from aplasia, as
inconclusive. Apart from this patient, we did not observe any effect
of therapy on assay score: Samples from patients who were
undergoing chemotherapy at the time of blood draw, or had
previously had chemotherapy (Supp. Table S2), gave neither system-
atically higher or lower scores than other patients. This argues
against the recent suggestion that the use of such agents may mask
the mutational signature of MMR deficiency (Shuen et al., 2019).
The variety of genetically‐confirmed CMMRD patients included
in the cohort allowed a limited analysis of variables that may affect
score. Patients homozygous for a hypomorphic variant in PMS2 had
low scores, which may be a consequence of their residual MMR
activity (Li et al., 2015). This suggests assay score may have
prognostic value by indicating the penetrance of germline variants.
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An association between age and frequency of microsatellite length
variants in PBLs has been detected in the general population
(Coolbaugh‐Murphy, Xu, Ramagli, Brown, & Siciliano, 2005), and
could lead to lower scores in younger CMMRD patients. We found no
correlation between age and score in the CMMRD patients overall
(r = 0.03, p = 0.89), although in patients from the same family, and
therefore sharing the same MMR gene variants, we generally
observed lower scores in younger compared with elder siblings
(Table S2). For example, Patient 22 (score = 3.54 and 7.39), who had
not presented with cancer, and was only 13 and 15 months old when
blood samples were taken, was 8 years younger than their higher
scoring sibling Patient 21 (score = 17.61). Variables such as clinical
history and age may also contribute to the variation observed in the
control scores. However, further analysis is beyond the scope of this
study.
The smMIP protocol has a low per sample cost and is scalable
(Hiatt et al., 2013), making our assay suitable for short turnaround
diagnostics. Furthermore, and in contrast to assays of MMR function
of patient cell extracts (Bodo et al., 2015; Shuen et al., 2019), our MSI
assay could be used for high‐throughput screening of large patient
cohorts or retrospective analysis of archived samples. The “missing”
CMMRD cases may be identified by screening unselected pediatric
cancer patients (Gröbner et al., 2018), and children suspected of NF1
or Legius syndrome who lack the causative NF1 or SPRED1 variants
(Suerink et al., 2019). The assay also offers a means to investigate
Lynch syndrome where CMMRD is a plausible explanation for an
exceptional phenotype, given that it can distinguish between patients
with mono‐ versus biallelic MMR variants. For example, it is
recognized that pathogenic PMS2 variants are less penetrant than
other MMR gene variants in the context of Lynch syndrome (Møller
et al., 2017; Ten Broeke et al., 2018), yet approximately 8% of CRCs
in carriers of pathogenic PMS2 variants are diagnosed before the age
of 30 and in the distal colon, much earlier than the mean onset at
48 years in probands and distinct from the proximal location that is
typical of Lynch syndrome (Goodenberger et al., 2016). Similarly,
CMMRD patients with hypomorphic PMS2 variants have a pre-
dominance of colorectal (i.e. not brain or hematological) malignancies
that are frequently diagnosed in early adulthood (Li et al., 2015).
Given the difficult diagnostic sequencing of PMS2 (Mandelker et al.,
2016), it is possible that some early onset Lynch syndrome cases
supposedly caused by one pathogenic PMS2 variant are actually
CMMRD with an unrecognized hypomorphic allele.
Functional assays can clarify CMMRD diagnosis when MMR VUS
are detected, but additional evidence is needed to confirm
pathogenicity of the variant. For this study, we enhanced VUS
classification by combining our assay with transcript analysis of the
entire coding region of the relevant gene (Etzler et al., 2008), which
excludes the presence of a different causative variant that may be
F IGURE 1 Score distribution of constitutional mismatch repair deficiency (CMMRD) and control samples. DNA samples from peripheral
blood leukocytes of genetically‐confirmed CMMRD, non‐CMMRD control, suspected CMMRD, and Lynch syndrome patients were sequenced
and scored (see Patients and methods). Suspected CMMRD patients had a clinical diagnosis and missense VUS detected in the indicated MMR
gene (Table S1). Score thresholds at 1.30 and 2.00 are equal to 5% and 1% probability a sample is from a control population, respectively
(horizontal dotted lines). The key indicates controls and the affected MMR gene in the CMMRD patients and Lynch syndrome patients
(ND = affected MMR gene not disclosed). § Patient 8, blood sample collected during recovery from aplasia. † patients homozygous for
hypomorphic PMS2 pathogenic variant. MMR: mismatch repair; VUS: variants of unknown significance
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missed by sequencing of genomic DNA. Through this approach, we
confirmed that cancer predisposition is associated with the MLH1
variant p.Val716Met despite its nonpathogenic classification in the
context of Lynch syndrome. This shows the importance of tailoring
MMR VUS classification depending on whether the associated
disorder is autosomal dominant Lynch syndrome or autosomal
recessive CMMRD.
In conclusion, our data confirm the results of Bodo et al. (2015),
and Ingham et al. (2013) that assessment of MSI is an adequate
measure of MMR function in nonneoplastic tissues for the diagnosis of
CMMRD. In addition, our smMIP and sequencing‐based assay over-
come the limitations of the previous MSI assays, providing a cheap and
accurate test for CMMRD irrespective of which MMR gene is affected
within clinical decision windows. It can also resolve ambiguous genetic
testing results, and, combined with transcript analysis, can classify VUS
in the context of CMMRD. Due to its low cost and scalability, the assay
is also suited to high‐throughput screening of at‐risk populations.
Hence, screening large patient cohorts with the presented assay and
its systematic application in clinical practice would better describe the
prevalence and phenotypic spectrum of CMMRD, as well as guide
clinical management, genetic counseling, and germline genetic testing
of patients and their families.
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